Tiffany Brumley
Family · Pocahontas, ARNPI 1962882902
Payments from drug & device makers
Across 238 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$711
- AstraZeneca$648
- Amgen$489
- AbbVie$385
- Pfizer$227
- Johnson & Johnson$161
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,843100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $711 |
| AstraZeneca | 29 | $648 |
| Amgen | 37 | $489 |
| AbbVie | 26 | $385 |
| Pfizer | 17 | $227 |
| Johnson & Johnson(2 entities) | 5 | $161 |
| Bayer | 7 | $144 |
| Lilly USA, LLC | 10 | $142 |
| Novartis | 9 | $132 |
| GSK | 8 | $122 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| Phathom Pharmaceuticals, Inc. | 8 | $79 |
| Sunovion Pharmaceuticals Inc. | 5 | $78 |
| Corcept Therapeutics | 3 | $78 |
| Sumitomo Pharma America, Inc. | 4 | $77 |
| EMD Serono, Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Exact Sciences | 2 | $30 |
| Astellas Pharma US Inc | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $23 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $14 |
| Sanofi | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$252
- FARXIGA$252
- BREZTRI$252
- INVEGA SUSTENNA$110
- INVEGA TRINZA$110
How this compares
$3,843 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $84,536 |
| EliquisApixaban | 31 | $23,259 |
| TrulicityDulaglutide | 24 | $23,183 |
| MounjaroTirzepatide | 17 | $17,581 |
| JardianceEmpagliflozin | 27 | $16,867 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $13,327 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $11,720 |
| MyrbetriqMirabegron | 18 | $9,792 |
| FarxigaDapagliflozin Propanediol | 11 | $8,494 |
| LinzessLinaclotide | 12 | $8,259 |
| GemtesaVibegron | 11 | $5,325 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,423 |
| Omeprazole | 103 | $1,315 |
| Aripiprazole | 18 | $1,243 |
| Gabapentin | 97 | $1,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $711 | $84,53674 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $142 | $40,76441 claims |
| PfizerEliquis | $227 | $23,25931 claims |
| GSKTrelegy Ellipta | $122 | $11,72020 claims |
| AstraZenecaFarxiga, Symbicort | $648 | $10,91722 claims |
| Astellas Pharma US IncMyrbetriq | $30 | $9,79218 claims |
| AbbVieLinzess | $385 | $8,25912 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $77 | $5,32511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.
Other family in Pocahontas
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.